XML 28 R21.htm IDEA: XBRL DOCUMENT v3.25.1
Restructurings
3 Months Ended
Mar. 31, 2025
Restructuring and Related Activities [Abstract]  
Restructurings

12. Restructuring

During the three months ended March 31, 2024, we implemented a restructuring plan to better align our organization to our two operating segments: MRD and Immune Medicine. We incurred aggregate restructuring costs of $1.0 million, primarily related to one-time termination benefits and ongoing benefit arrangements, which were paid as of June 30, 2024.